Search for: "Beecham v. Beecham" Results 21 - 40 of 434
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
14 Jul 2019, 5:03 pm by Larry
SmithKline Beecham Corp., 567 US 142, 155 (2012) which was further quoting Bowen v. [read post]
29 May 2019, 12:22 pm
  If the defendant "knew the risk and decided it was best not to remove it" then that is a factor in favor of maintaining the status quo and granting an injunction (see Aldous LJ in SmithKline Beecham v Apotex [2003] FSR 31 at [40]; see also Arnold J in Warner-Lambert v Actavis [2015] EWHC 72 at [133]). [read post]
24 Apr 2019, 12:12 pm by Dennis Crouch
– DC Smithkline Beecham v. [read post]
4 Nov 2018, 10:56 am by Schachtman
SmithKline Beecham Corp., No. 3516 EDA 2015, 2017 WL 1902905 *6 (Phila. [read post]
3 Jul 2018, 5:13 am
However, neither court commented on whether the EPO’s requirement that an overlapping range should have a technical effect is consistent with the UK novelty requirement established by Lord Hoffmann in Synthon BV v Smithkline Beecham plc [2005] UKHL 59. [read post]
19 Apr 2018, 11:37 pm
Now, as  we finally have the decision itself (Decision nr NCL 001, of the 16th of March 2018), there are a number of interesting points to discuss.Background of the caseOn 12 October 2009, Smith Kline Beecham Limited ( “GSK” ) filed a Community plantvariety right (CPVR) application No 2009/1980 for the variety ‘Ben Starav’ of the species Ribes nigrum L.. [read post]
9 Feb 2018, 7:54 am by Dennis Crouch
Co., 350 F.3d 1371 (finding “superimposed” to describe a structural relationship and not a process); SmithKline Beecham Corp. v. [read post]
18 Sep 2017, 1:36 am
The first Zurich IP Retreat was held on Friday/Saturday 8/9 September 2017 on the shores of lake Zurich, organized by INGRES and ETH Zurich, in honour of Dr. [read post]